The prevalence of overtreatment of osteoporosis: results from the PAADRN trial
- 118 Downloads
Overtreatment of osteoporosis increases costs and puts patients at unnecessary risk of experiencing adverse drug events. In the Patient Activation After DXA Receipt Notification (PAADRN) trial, we found that 8% of individuals with no indication for therapy were recommended a new osteoporosis medication or continuation of an existing medication.
There is a robust body of literature addressing undertreatment in osteoporosis, but limited data addressing overtreatment. Understanding overtreatment is important to minimize harm and decrease costs.
One of the pre-specified post hoc analyses of the PAADRN trial, a randomized, controlled, pragmatic clinical trial, was to quantify and identify risk factors associated with osteoporosis overtreatment. PAADRN included patients ≥ 50 years of age presenting for bone density testing between February, 2012, and August, 2014, at three US healthcare systems. We assessed 20,397 patients for eligibility and randomized 7749. Intervention patients received a tailored letter containing their dual-energy X-ray absorptiometry (DXA) results and an educational osteoporosis brochure. Control patients received usual care. Using the National Osteoporosis Foundation treatment guidelines, we defined overtreatment as the receipt of osteoporosis pharmacotherapy 12 weeks after DXA when treatment was not indicated. We evaluated the relationship between the following baseline variables—sex, race/ethnicity, educational attainment, and differences across health systems—and overtreatment using a series of multivariable logistic regression models.
Among 3602 patients with no apparent indication for osteoporosis treatment, 292 (8.1%; 95% CI, 7.22 to 9.00%) received a new prescription for osteoporosis pharmacotherapy or were instructed to continue an existing medication (presumed overtreatment). Presumed overtreatment was more common among participants with prior DXA history, those who reported a history of osteoporosis or low bone mass, and those referred for testing by family medicine providers.
In our sample of older adults, overuse of osteoporosis pharmacotherapy was only 8.1%. Nevertheless, overtreatment exposes patients to possible risk with negligible chance of benefit and should be minimized.
clinicaltrials.gov identifier: NCT01507662
KeywordsOsteoporosis Therapeutics Aging DXA Fracture risk assessment
This work was supported by R01 AG033035 (Cram/Wolinsky) from the NIA at NIH. Dr. Cram is supported by a K24 AR062133 award from NIAMS at the NIH. Dr. Wright is supported by a K12 HS023009 award from AHRQ. Dr. Saag is supported by a K24 AR052361 award from the NIAMS at the NIH.
Role of the sponsor
The NIA had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Study concept and design: Cram, Edmonds, Jones, Roblin, Saag, Wolinsky
Acquisition of data: Edmonds, Hall
Analysis and interpretation of data: Jones, Lou, Wolinsky
Drafting of the manuscript: Cram, Hall, Lou, Wolinsky, Wright
Critical revision of the manuscript: Cram, Edmonds, Hall, Jones, Lou, Roblin, Saag, Wolinsky, Wright
Statistical analysis: Jones, Lou
Obtained funding: Cram, Roblin, Saag
Administrative, technical, or material support: Edmonds, Hall, Wolinsky
Study supervision: Cram, Edmonds, Hall, Wolinsky
Compliance with ethical standards
Cram, Jones, Lou, and Wolinsky had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Conflicts of interest
P Cram, M Jones, F Wolinsky, S Edmonds, S Hall, Y Lou, and D. Roblin have no conflicts of interest. NC Wright has received unrestricted grant support from Amgen for work unrelated to this project, and is a consultant to Pfizer. KG Saag has received grants from Amgen, Eli Lilly, and Merck and has served as a paid consultant to Amgen, Eli Lilly, and Merck.
- 3.Looker AC, Borrud LG, Dawson-Hughes B, Shepherd JA, Wright NC Osteoporosis or low bone mass at the femur neck or lumbar spine in older adults: United States, 2005–2008. NCHS Data Brief 2012(93):1–8Google Scholar
- 5.Pfister AK, Welch CW, Emmett M. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2011;155(4):275–276; author reply 6–7Google Scholar
- 14.Fenton JJ, Robbins JA, Amarnath AL, Franks P (2016) Osteoporosis overtreatment in a regional health care system. JAMA Intern Med:1–3Google Scholar
- 17.Wolinsky FD, Lou Y, Edmonds SW, Hall SF, Jones MP, Wright NC et al (2016) Activating patients with a tailored bone density test results letter and educational brochure: the PAADRN randomized controlled trial. J Clin DensitomGoogle Scholar
- 24.Sanfelix-Gimeno G, Hurtado I, Sanfelix-Genoves J, Baixauli-Perez C, Rodriguez-Bernal CL, Peiro S (2015) Overuse and underuse of antiosteoporotic treatments according to highly influential osteoporosis guidelines: a population-based cross-sectional study in Spain. PLoS One 10(8):e0135475CrossRefGoogle Scholar